skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
IMT-1012 Immunotherapeutic Vaccine (Code C77863)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: IMT-1012 Immunotherapeutic Vaccine

Definition: A multi-peptide cancer vaccine with potential immunostimulating and antineoplastic activities. IMT-1012 immunotherapeutic vaccine contains twelve different synthetic peptides or tumor associated antigens (TAAs), including cyclin I (CCNI), cyclin-dependent kinase CDC2, EDDRI and TACE/ADAM17, each of which is involved in a different pathway associated with tumor growth, survival, and metastasis. Each antigen in the vaccine elicits a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing that antigen. This multi-antigen/multi-pathway targeting strategy provides broad immunotherapeutic coverage with respect to tumor complexity and heterogeneity and may result in enhanced vaccine efficacy.

Display Name: IMT-1012 Immunotherapeutic Vaccine

Label: IMT-1012 Immunotherapeutic Vaccine

NCI Thesaurus Code: C77863 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL383604  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
IMT-1012 Immunotherapeutic Vaccine
OCPM Immunotherapeutic Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 596541
PDQ Open Trial Search ID 596541 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C77863
Contributing_Source CTRP
Legacy_Concept_Name IMT-1012_Immunotherapeutic_Vaccine
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom